Teva Pharmaceutical Industries Limited (TEVA) Highlights Long-Acting Injectable Advancements for Schizophrenia at 2025 Psych Congress

Teva Pharmaceutical Industries Limited (NYSE:TEVA) has unveiled new data at the 2025 Psych Congress Elevate, highlighting significant advances in schizophrenia treatment. Real-world studies show that UZEDY (risperidone), a long-acting injectable suspension administered subcutaneously every one or two months, delivers better outcomes compared to daily oral antipsychotics.

Teva Pharmaceutical Industries Limited (TEVA) Highlights Long-Acting Injectable Advancements for Schizophrenia at 2025 Psych Congress

A medical professional discussing the prescription-only therapy with a patient.

Patients on UZEDY experienced lower relapse rates (9.0% vs. 15.4% for second-generation oral antipsychotics), longer time to relapse, improved adherence (71.3% vs. 52.8%), and greater treatment persistence. UZEDY users also had fewer inpatient, outpatient, and emergency department visits, shorter hospital stays, and reduced overall healthcare costs.

Additionally, Teva Pharmaceutical Industries Limited (NYSE:TEVA) presented Phase 3 SOLARIS trial results for TEV-‘749, an investigational once-monthly subcutaneous olanzapine formulation. After more than 3,400 injections, there were no suspected or confirmed cases of post-injection delirium/sedation syndrome (PDSS), a key safety concern with existing olanzapine injectables. The safety profile of TEV-‘749 aligned with approved olanzapine options, and the drug met its primary efficacy endpoint across all dosing groups.

These findings reinforce Teva Pharmaceutical Industries Limited (NYSE:TEVA)’s leadership in developing innovative, long-acting schizophrenia therapies designed to improve patient outcomes and address critical gaps in current treatment options.

While we acknowledge the potential of TEVA to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than TEVA and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best Cancer Stocks to Invest in for Long-Term Gains and 10 Most Oversold Stocks to Buy According to Billionaires.

Disclosure: None.